Video Interview: TLC Delivers Sustained Release And Improved Tissue Targeting
This article was originally published in Scrip
Ensuring difficult-to-deliver drugs get to target sites is a common challenge for many pharma and biotech companies. George Yeh, president of Taiwan Liposome Co, tells Mike Ward, global director of content for Informa's pharma insights portfolio, how his company is developing more effective treatments for oncologic and ophthalmologic diseases and for pain using proprietary technology that provides sustained release and improved tissue targeting. He explains how the company's offering, which is underpinned by lipid-based formulation and scale-up for parenteral drugs using micelles and nanoparticles, helps optimize the pharmacokinetics of drugs for better efficacy and lower toxicity, and thus prolong the product lifecycle of branded drugs. Specifically, he explains how approved, commercialized drugs and major partners validate TLC's lipid-based nano-delivery technology and its ability to bring difficult-to-manufacture, difficult-to-scale-up products to market.
You may also be interested in...
Public Company Edition: With returns for newly public biopharma companies rising, seven more jumped in line to go public in the US between the beginning of February and early March, while two drug developers launched IPOs in the EU. Meanwhile, already public companies keep raising gobs of cash.
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.